Evidence map›Paper›PMID 39497115›Full record

ArticleBMC ophthalmology2024

Protective effect of apelin-13 in lens epithelial cells via inhibiting oxidative stress-induced apoptosis.

Xue Li, Chao Gu, Qiumei Hu, Liqin Wang, Ya Zhang, Ling Yu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC ophthalmology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Apelin/APJ: Another Player in the Cancer Biology Network.International journal of molecular sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xue Li *Department of Ophthalmology, Daping Hospital, Army Medical Center, Army Medical University, Chongqing, 400042, China.
Chao Gu *Department of Ophthalmology, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan Province, 646000, China.
Qiumei HuDepartment of Ophthalmology, Daping Hospital, Army Medical Center, Army Medical University, Chongqing, 400042, China.
Liqin WangDepartment of Ophthalmology, Daping Hospital, Army Medical Center, Army Medical University, Chongqing, 400042, China.
Ya ZhangDepartment of Ophthalmology, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan Province, 646000, China.
Ling YuDepartment of Ophthalmology, Daping Hospital, Army Medical Center, Army Medical University, Chongqing, 400042, China. oculistlingyu@hotmail.com.

Funding

National Natural Science Foundation of China NO.82070962National Natural Science Foundation of China NO.82201164
6 · The paper itself

Abstract

backgroundIt is widely accepted that glaucoma-induced oxidative stress expedites cataracts' process. Therefore, we examined the effects of apelin-13 against oxidative stress-induced damage in human lens epithelial cells (HLECs) and investigated the potential pathogenic mechanism of acute primary angle-closure glaucoma.

methodsThis experiment included five groups: control, H

resultApelin-13 reversed the H CONCLUTIONS: Apelin-13 reduced oxidative damage and apoptosis in HLECs through APJ. These results demonstrate that apelin-13 can be employed as a potential drug for glaucoma with cataracts to delay the progression of cataracts.

Indexed as

ApoptosisCell SurvivalEpithelial CellsHydrogen PeroxideIntercellular Signaling Peptides and ProteinsLens, CrystallineMembrane Potential, MitochondrialOxidative StressCells, CulturedHumansapelin-13 peptideHydrogen PeroxideIntercellular Signaling Peptides and ProteinsAcute primary angle-closure glaucomaApelin-13ApoptosisCataractsOxidative stress

Identifiers

PMID39497115
PMCPMC11533313

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.